Show simple item record

European Association of Urology Guidelines on the Management of Female Non-neurogenic Lower Urinary Tract Symptoms. Part 2 : Underactive Bladder, Bladder Outlet Obstruction, and Nocturia

dc.contributor.authorArlandis, Salvador
dc.contributor.authorBø, Kari
dc.contributor.authorCobussen-Boekhorst, Hanny
dc.contributor.authorCostantini, Elisabetta
dc.contributor.authorde Heide, Monica
dc.contributor.authorFarag, Fawzy
dc.contributor.authorGroen, Jan
dc.contributor.authorKaravitakis, Markos
dc.contributor.authorLapitan, Marie Carmela
dc.contributor.authorManso, Margarida
dc.contributor.authorArteaga, Serenella Monagas
dc.contributor.authorNambiar, Arjun K.
dc.contributor.authorRiogh, Aisling Nic An
dc.contributor.authorO'Connor, Eabhann
dc.contributor.authorOmar, Muhammad Imran
dc.contributor.authorPeyronnet, Benoit
dc.contributor.authorPhé, Veronique
dc.contributor.authorSakalis, Vasileios I.
dc.contributor.authorSihra, Néha
dc.contributor.authorTzelves, Lazaros
dc.contributor.authorvan Poelgeest-Pomfret, Mary Lynne
dc.contributor.authorvan den Bos, Tine W.L.
dc.contributor.authorvan der Vaart, Huub
dc.contributor.authorHarding, Christopher K.
dc.date.accessioned2023-02-16T00:11:25Z
dc.date.available2023-02-16T00:11:25Z
dc.date.issued2022-02-16
dc.identifier.citationArlandis , S , Bø , K , Cobussen-Boekhorst , H , Costantini , E , de Heide , M , Farag , F , Groen , J , Karavitakis , M , Lapitan , M C , Manso , M , Arteaga , S M , Nambiar , A K , Riogh , A N A , O'Connor , E , Omar , M I , Peyronnet , B , Phé , V , Sakalis , V I , Sihra , N , Tzelves , L , van Poelgeest-Pomfret , M L , van den Bos , T W L , van der Vaart , H & Harding , C K 2022 , ' European Association of Urology Guidelines on the Management of Female Non-neurogenic Lower Urinary Tract Symptoms. Part 2 : Underactive Bladder, Bladder Outlet Obstruction, and Nocturia ' , European Urology . https://doi.org/10.1016/j.eururo.2022.01.044en
dc.identifier.issn0302-2838
dc.identifier.otherPURE: 212440549
dc.identifier.otherPURE UUID: ccff4894-cdac-4188-8414-fa96e38d788e
dc.identifier.otherScopus: 85124657901
dc.identifier.otherScopus: 85124657901
dc.identifier.otherORCID: /0000-0002-1597-3126/work/112135192
dc.identifier.urihttps://hdl.handle.net/2164/20067
dc.descriptionFunding Information: Financial disclosures: Salvador Arlandis certifies that all conflicts of interest, including specific financial interests and relationships and affiliations relevant to the subject matter or materials discussed in the manuscript (eg, employment/affiliation, grants or funding, consultancies, honoraria, stock ownership or options, expert testimony, royalties, or patents filed, received, or pending), are the following: Salvador Arlandis has received company speaker honoraria from Astellas Pharma S.A., Bayer Hispania S.L., and Lacer-Holliste; has received honoraria for consultation from Presurgy S.L., Boston Scientific Europe, and Coloplast Productos Medicos; has participated in clinical trials by GlaxoSmithKline, Astellas, Ipsen, and Urovant; has received travel grants from Astellas Pharma S.A., WellSpect, Lacer, and Rovi; and has been a company consultant for Lacer Laboratories. Christopher K. Harding is a company consultant for Teleflex Medical; has received speaker honoraria from Astellas, Allergan, and Medtronic; has participated in clinical trials by Medtronic; has received fellowship and travel grants from Medtronic; and has received research support from the National Institute for Health Research and The Urological Foundation. Marie Carmela Lapitan has received speaker honoraria from Astellas, AstraZeneca, and GSK. Elisabetta Costantini has received research support from S&R Farmaceutici. Jan Groen has participated in clinical trials by Neuspera Medical Inc. Veronique Phé has received speaker honoraria from Medtronic and Viatris and is a company consultant for Allergan and Coloplast. Huub van der Vaart has ownership interest in a patent with Ligalli B.V.; is a director of Berman Clinics; receives royalties from NVOG; is participating in clinical trials by UroGyn; and receives research support from ZonMw and NWO-TTW. Benoit Peyronnet is a company consultant for Boston Scientific. Lazaros Tzelves receives research support from the National and Kapodistrian University of Athens and the ASCAPE Project and is participating in a clinical trial by the ASCAPE Project. The remaining authors have nothing to disclose.en
dc.language.isoeng
dc.relation.ispartofEuropean Urologyen
dc.rights© 2022. This manuscript version is made available under the CC-BY-NC-ND 4.0 license https://creativecommons.org/licenses/by-nc-nd/4.0/en
dc.subjectBladder outlet obstructionen
dc.subjectConservative managementen
dc.subjectEuropean Association of Urology guidelinesen
dc.subjectFemale lower urinary tracts symptomsen
dc.subjectNocturiaen
dc.subjectUnderactive bladderen
dc.subjectR Medicineen
dc.subjectUrologyen
dc.subject.lccRen
dc.titleEuropean Association of Urology Guidelines on the Management of Female Non-neurogenic Lower Urinary Tract Symptoms. Part 2 : Underactive Bladder, Bladder Outlet Obstruction, and Nocturiaen
dc.typeJournal articleen
dc.contributor.institutionUniversity of Aberdeen.Other Applied Health Sciencesen
dc.contributor.institutionUniversity of Aberdeen.Academic Urology Uniten
dc.description.statusPeer revieweden
dc.description.versionPostprinten
dc.identifier.doihttps://doi.org/10.1016/j.eururo.2022.01.044
dc.date.embargoedUntil2023-02-16
dc.identifier.urlhttp://www.scopus.com/inward/record.url?scp=85124657901&partnerID=8YFLogxKen


Files in this item

Thumbnail
Name:
Arlandis_etal_EAU_Guidelines_O ...
Size:
367.4Kb
Format:
PDF
View/Open

This item appears in the following Collection(s)

Show simple item record